Micah Benson

Micah Benson

Company: KSQ Therapeutics

Job title: Senior Vice President & Head of Immunobiology


CRISPR/Cas9 Engineered TIL for Enhanced Anti-Tumor Function 11:00 am

CRISPR/Cas9 screens identify top T cell targets enhancing the antitumor potency of engineered TIL (eTILTM) against solid tumors Combination CRISPR screens (CRISPR2) determine the top T cell target combinations to further enhance the potency of eTILTM KSQ-001 is a CRISPR/Cas9 engineered eTILTMRead more

day: Conference Day 2

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.